UiPath (NYSE:PATH – Free Report) had its price target reduced by BMO Capital Markets from $16.00 to $11.50 in a report ...

Bank of Montreal’s veteran oil and gas analyst is making the case for a four-way mega merger in Western Canada’s Montney Formation, arguing such a deal would boost scale and broaden investor appeal.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...

U.S. government debt rallied aggressively overnight and into Tuesday’s trading session, pushing yields below key technical levels in a way that appeared to be shaking confidence in the broader market.

BMO Capital raised the firm’s price target on Okta (OKTA) to $130 from $105 and keeps a Market Perform rating on the shares. The firm had been ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of ...

BMO Capital analyst Keith Bachman initiated coverage of SailPoint (SAIL) with an Outperform rating and $26 price target The firm believes ...

(Bloomberg) -- Bank of Montreal and Bank of Nova Scotia kicked off Canadian bank earnings season with strong results from their capital-markets divisions amid an increase in trading activity.